Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T combined with ASCT for high-risk relapsed/refractory large B-cell lymphoma
ChiCTR2600116310Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL) and 2 more, sponsored by Zhejiang Cancer Hospital. Primary endpoint: One-year progression-free survival rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)central nervous system lymphomafollicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on ChiCTR2600116310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116310.